Avantium appoints bioplastics specialist

Jeffrey Kolstad joins as chief scientist from NatureWorks

Jeffrey Kolstad has joined Avantium as chief scientist, strengthening the Dutch firm’s team in developing next-generation bioplastics using its YXY technology.

Previously chief scientist at NatureWorks (formerly Cargill-Dow), Kolstad was one of the founding members of the team that developed and commercialised PLA (polylactic-acid), a bio-based polymer. He was also responsible for managing NatureWorks’ IP portfolio and strategy.

Prior to this Kolstad worked in the corporate research centres at Cargill and Amoco Oil Company.

You may also like

Research & Development

Avantium spins out pharma business

To create an independent business called Crystallics, specialising in solid state research
Regulatory
Tasrif Pharmaceutical granted second US patent for CD155-targeting antibody developed with Abzena's humanisation and immunogenicity platforms

Tasrif Pharmaceutical granted second US patent for CD155-targeting antibody developed with Abzena's humanisation and immunogenicity platforms

Expanded intellectual property supports development of humanised anti-CD155 antibody and next-generation cancer immunotherapy modalities
Regulatory
Promatix secures Innovate UK grant to advance cis-bispecific ADC programme

Promatix secures Innovate UK grant to advance cis-bispecific ADC programme

Funding will support manufacturing scale-up, preclinical studies and IND-enabling safety work for PBS293-exatecan
Manufacturing
Thermo Fisher Scientific launches new general purpose centrifuges with natural refrigerant cooling

Thermo Fisher Scientific launches new general purpose centrifuges with natural refrigerant cooling

New X2 and S2 Series centrifuges combine precise performance with improved sustainability for research, biopharma and clinical laboratories
Research & Development
Digitalisation: more space for research and development in Salzburg, Austria

Digitalisation: more space for research and development in Salzburg, Austria

COPA-DATA is investing €15 million in the project, underlining its long-term commitment to Salzburg and Austria as a location for technology, research and innovation
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development
The future of science is built on networks, not laboratories

The future of science is built on networks, not laboratories

More often than not, life science innovation depends on decades of international collaboration, shared infrastructure and open exchange of data, Plamena Markova, Head of International Relations at the European Molecular Biology Laboratory (EMBL), tells Dr Kevin Robinson
Research & Development
Parsortix CTC platform detects ADC targets in breast and ovarian cancer

Parsortix CTC platform detects ADC targets in breast and ovarian cancer

A new, peer-reviewed study has shown that CelLBxHealth’s Parsortix platform can detect ADC-relevant targets on circulating tumour cells, including TROP-2 on EpCAM-low cells in triple-negative breast cancer
Subscribe now